GHN Pharma Nordic and Welcare Industries increases the cooperation regarding the Jalosome line with JALOSOME® ORAL BARRIER.
JALOSOME® ORAL BARRIER is a Medical Device indicated for the treatment of painful symptoms of oral mucositis. Oral mucositis is a very common side effect in patients receiving radiotherapy or chemotherapy. Studies indicate that 30-40% of cancer patients undergoing treatment are affected. Mucositis significantly affects the quality of life of patients with symptoms such as dry mouth, pain, burning, ulcers, difficulty eating, swallowing and speaking.
JALOSOME® ORAL BARRIÄR offers a pain-relieving action thanks to its strong mucoadhesive properties that form a protective barrier on the oral mucosa. The protective film defends the mucosa from external insults, promoting wound healing by keeping the environment hydrated and lubricated. The protective barrier and its properties also make Jalosome Oral Barrier suitable for other conditions in the oral cavity such as aphthous ulcers and ulcers, e.g. in connection with implants or oral surgery.
Earlier GHN have lunched Jalosome® Soothing Gel a Patented Medical Device for the reduction of skin inflammations and related pain due to chemo and radiotherapy, Graft versus Host Disease (GvHD), dermatitis, erythema, and skin disorder of any aetiology. 30 – 50 % of patients with cancer undergoes radiotherapy treatment each year and around 95% will have some kind of skin reaction. Most of the new cases of cancer people will be given chemotherapy. 12-35 %, of these patients will have skin reactions for any given chemo.
”With Jalosome Oral Barrier ned Jalosome sotning gel are we able to offer a total program treating potential side effects of radio and Chemotherapy” Tina Madsen Sandström, CEO
For More information Contact moc.a1686435673mrahp1686435673nhg@c1686435673idron1686435673ofni1686435673